Targeting the Roots of Neurodegeneration
Transposon Therapeutics, Inc. (transposonrx.com) scores 62 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 8th percentile of 19661 Healthcare brands.
Transposon Therapeutics, Inc. is a San Diego-based clinical-stage biopharmaceutical company developing TPN-101 (Censavudine) and other LINE-1 reverse transcriptase inhibitors. Its therapeutic focus is on rare, debilitating neurodegenerative diseases, including progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). The company aims to address the underlying biological mechanisms of neurodegeneration through novel, first-in-class therapies, targeting patients, healthcare providers, researchers, and investors in the biopharmaceutical sector.
| Brand Name | Transposon Therapeutics, Inc. |
|---|---|
| Domain | transposonrx.com |
| Industry | Healthcare |
| Headquarters | San Diego, United States |
| Main Competitors | Rome Therapeutics, Alector (79/100), Denali Therapeutics (77/100), AviadoBio, Ionis Pharmaceuticals (79/100), Biogen (78/100) |
Moz Domain Authority 20/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseas…" (Meta description: 37 words. No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache.
Social footprint: verified profiles on Instagram; no detected presence on X (Twitter), LinkedIn, Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Transposon Therapeutics, Inc.'s main competitors in Healthcare: Alector (79/100), Denali Therapeutics (77/100), Ionis Pharmaceuticals (79/100), Biogen (78/100).
Sources: Brand Analyzer scan
Transposon Therapeutics' primary product in development is TPN-101 (Censavudine), a LINE-1 reverse transcriptase inhibitor being studied for its potential to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company is also developing other compounds in the same drug class.
Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, United States, focused on developing therapies for rare neurodegenerative diseases.
Transposon Therapeutics, Inc. has low AI-search visibility, scoring 21/100 on Brand Analyzer's AI visibility composite (visibility 19, trust 12, recommendation 37). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Transposon Therapeutics, Inc. scores 37/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Transposon Therapeutics is known for pioneering TPN-101 (Censavudine), a LINE-1 reverse transcriptase inhibitor being investigated as a treatment for PSP, ALS, and FTD-conditions that currently lack effective therapies.
Transposon Therapeutics, Inc. can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
The company's work is intended for patients suffering from rare neurodegenerative diseases such as PSP, ALS, and FTD. Its stakeholders also include healthcare providers, researchers, and investors in the biopharmaceutical industry who are involved in clinical development and funding of new therapies.
Transposon Therapeutics, Inc. scores 21/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Transposon Therapeutics, Inc. has a weak AI-visibility profile at 21/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (37/100) and its weakest is trust (12/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 20/100 and thin schema.org structured data.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Transposon Therapeutics, Inc.: Justice Yoga | MDH Advisors (62/100), BlueSky At-Home Veterinary Care (62/100), Vännäs kommun (62/100), VantageFit (62/100).
A step up - brands to learn from: Zentralwohlfahrtsstelle der Juden in Deutschland e.V. (71/100), ZT Corporate (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.